Cryobanks International India Pvt. Ltd, a global leader, has now focused on improving its services and facilities, health and safety of the people with a new name as “Cryoviva Biotech Private Limited”. The higher authority has announced that cord blood banking business for families will now offer the ability to extract more cells from the tissue surrounding the umbilical cord vessels which are a very rich source of mesenchymal stem cells (MSCs).

This new capability is exclusive to Cryoviva Biotech Private Limited, the only cord blood banking roof with patent rights to expand stem cells from cord tissue as well as extract and develop stem cells from the tissue around the cord vessels. This proprietary service is offered, as part of the current cord blood stem cell services to expectant parents through an exclusive and high-quality umbilical cord blood stem cell processing. The banking facilities are for both private and public donation purposes. The company is working towards national and international collaborations to provide the “best of class” services in stem cell industry in India.

“With the new pathway, we are working towards national and international collaborations to provide the best-in-class facilities in stem cell industry in India. Moreover, with the vision of being the best and high processing and storage technology in near future, we have propounded our services approved by international authorities,” acknowledged by a senior board member of Cryoviva.

Even after becoming Cryoviva Biotech Pvt. Ltd. from Cryobanks International India Pvt. Ltd. the health care facility will continue to provide the customers access to a very rich source of cord blood cells from umbilical cord tissue. The use of innovative technology will only increase their chances of potential success and benefit from possible therapeutic applications. Also, the up gradation will further distinguish Cryoviva’s portfolio of offerings in the area of cord tissue banking.

Proper research in Cryoviva on stem cells is intended to achieve accurate results that may guide clinical studies of stem cell applications for diseases, including rheumatoid arthritis and osteoarthritis, different cancers like leukaemia, anaemia, leukemia, and lymphoma.